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Preventing premature non-communicable disease mortality necessitates a thorough re-
view of one of the most important risk factors for stroke, which is atrial fibrillation (AF).
The latter and AF-related stroke are still considered to be problems of high-income coun-
tries and are frequently overlooked in low- and middle-income countries (LMICs). In this
narrative review, we provide an overview of studies that evaluated at least one of the
following determinants of AF burden in LMICs: current epidemiology and trends, stroke
prevention, health outcomes, and economic burden. Studies focusing on samples close to
the general population (including community- and primary care-based samples) indicate
sex-specific prevalence rates up to 7.4% in LMICs. Although AF prevalence is still higher
in high-income countries than LMICs, the gap in AF burden between these two groups has
been reducing in the past three decades. Oral anticoagulant (OAC) therapy for stroke
prevention is underused in LMICs, and there are little data on OAC therapy in relation to
stroke risk scores, such as CHA2DS2-VASc. Available data also points to higher morbidity
and mortality for patient with AF in LMICs than their counterparts in high-income coun-
tries. Data on the consequent economic burden in LMICs is scarce, but it is reasonable to
consider it will follow the same trend as that observed for health outcomes. Raising the
visibility of AF as a public health problem in LMICs is necessary as a first step to providing
adequate care for patients with this condition.
†NIHR Global Health Group on Atrial Fibrillation Management Investigators (alphabetical): Ajini Arasalingam, Isabela Bense~nor, Peter Brocklehurst,
Kar Keung Cheng, Mei Feng, Alessandra C. Goulart, Sheila Greenfield, Yutao Guo, Mahesan Guruparan, Gustavo Gusso, Wang Hao, Lindsey
Humphreys, Balachandran Kumarendran, Kate Jolly, Sue Jowett, Emma Lancashire, Deirdre A. Lane, Xuewen Li, Yanguang Li, Gregory Y.H. Lip (Co-
PI), Trudie Lobban, Paulo Lotufo, Semira Manseki-Holland, David Moore, Krishnarajah Nirantharakumar, Rodrigo Olmos, Itamar S. Santos, Alena
Shantsila, Isabelle Szmigin, Kumaran Subaschandren, Rajendra Surenthirakumaran, G. Neil Thomas (Co-PI), and Jingya Wang.
*Corresponding author. Tel: þ55 11 3091 9300, Email: itamarss@usp.br
Published on behalf of the European Society of Cardiology. VC The Author(s) 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in
any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal Supplements (2020) 22 (Supplement O), O61–O77
The Heart of the Matter
doi:10.1093/eurheartj/suaa181
Introduction
In October 2015, the World Health Organization (WHO)
launched the WHO 25 25 initiative with the specific goal
of achieving a 25% decrease in premature mortality due to
non-communicable diseases (NCDs) by 2025. The initiative
involved government institutions, scientific and profes-
sional societies, academic institutions, and health policy
bodies across the world. In the context of NCD mortality,
stroke is particularly relevant, representing the second
largest cause of death globally1; thus, adequate stroke pre-
vention is a key factor to reducing premature NCD
mortality.2
Preventing premature NCD mortality due to stroke
necessitates a thorough review of one of the most impor-
tant risk factors for stroke: atrial fibrillation (AF). Dai et
al.3 estimated that in 2017 there were 37.6 million preva-
lent AF cases and 3.1 million incident cases of AF globally.
Moreover, AF contributed to290000 deaths globally, with
an age-standardizedmortality rate of 4.0/100000 people.
The healthcare burden of AF and AF-related stroke are
still mostly (and erroneously) considered as problems of
wealthy countries, and frequently overlooked in low- and
middle-income countries (LMICs). In fact, according to the
Global Burden of Disease (GBD) 2017 data,3,4 the five coun-
tries or territories with the highest age-standardized AF or
flutter prevalence (New Zealand, USA, Sweden, Australia,
and Austria) and incidence (USA, New Zealand, Sweden
Greenland, and Australia) rates are high-income countries.
However, although AF prevalence rates are lower in LMICs,
61% of global disability-adjusted life years (DALYs) are lo-
cated in these countries.4
Although gaps in the current literature still exist, there is
a substantial amount of data registering the impact of AF in
LMICs. Even more importantly, it also highlights the in-
creasing importance of AF epidemiology in this country
group in the near future.
In this review article, we discuss the epidemiology, use
of medication for stroke prevention, outcomes, and eco-
nomic consequences of AF in LMICs. Our aim was to provide
an overview of the impact of this disease on LMIC
populations.
Methodology
In this narrative review, the LMIC group was defined
according to the current World Bank criteria5
(Supplementary material online, Appendix S1). This classi-
fication categorizes countries according to the gross na-
tional income per capita as low-income [ US dollars (USD)
1035], lower-middle income (USD 1036–4045), upper-
middle income (USD 4046–12 535), and high-income (USD
12536) groups. Low- and middle-income countries refer to
the union of low, low-middle, and upper-middle income
groups. We included articles published since 2000 that
evaluated at least one of the following determinants of AF
burden in LMICs: current epidemiology and trends, stroke
prevention, health outcomes, and economic burden. We
also included articles that evaluated high-income countries
but which retrieved LMICs data. It must be acknowledged,
however, that the World Bank income groups may still yield
high intragroup heterogeneity. However, other classifica-
tions (as the International Monetary Fund classification of
countries based on their level of development, the United
Nations Development Programme Human Development
Index, or the Global Burden of Disease Study Socio-
Development Index) are very similar. All classifications use
GNI or other socioeconomic indicators highly correlated
with GNI as their main criteria. Because of the high intra-
group heterogeneity, in most cases, we present original ar-
ticle results according to the geographical location of the
sample.
Current epidemiology and trends
The reported prevalence of AF in LMICs is heterogeneous.
Studies focusing on samples close to the general population
(including community- and primary care-based samples) in-
dicate sex-specific prevalence rates up to 7.4% (Figure 1
and Supplementary material online, Table S1)9–36 and most
show prevalence rates between 0.5% and 3.0%. This wide
variation may be at least partly explained by differences in
study design and populations, mainly age of participants
and AF subtype and duration. As expected, prevalence
rates are even higher when specific groups are studied,
such as those with heart failure,6 stroke,7 or rheumatic
heart disease.8
The relatively low prevalence of AF in the general popu-
lation in LMICs compared with high-income countries
should not be interpreted as a sign of a stable low burden
of AF in LMICs.37 As shown in Figure 2, epidemiological
trends in the past 30years have demonstrated a reducing
gap between high-income countries and LMICs for AF-
related burden. Data in this figure were extracted from the
GBD results tool (http://ghdx.healthdata.org/gbd-results-
tool). Detailed information about the GBDmethodology for
these estimates can be found elsewhere.38 Figure 1 shows
age-standardized rates for multiple GBD metrics (preva-
lence, incidence, deaths, years of life lost, years lived with
disability, and disability-adjusted life years) from 1990 to
2017. Rates for each group from 1990 to 2017 are pre-
sented in proportion to 1990 levels (presented as 100%, in
the horizontal dotted line).
These plots, together with recently published GBD AF
data,3 highlight two main patterns. First, for metrics
mainly focused on morbidity [prevalence, incidence, and
years lived with disability (YLD)]; global rates are falling
mainly due to a decreasing trend in high-income countries.
Comparing 1990 and 2017 rates, the steepest decreases in
these metrics were observed in Portugal, Italy, Spain,
Andorra, and France, all of which are high-income
countries.
On the other hand, metrics that are influenced by higher
and/or premature mortality [deaths and years of life lost
(YLL)] or represent total disease burden (DALY) have a dif-
ferent pattern. Although global rates are relatively stable,
there are important increases in these rates for the LMIC
group. A detailed look at the information by country
reveals that, except for Bahrain (a high-income country)
and Burkina Faso (a low-income country), the 10 countries
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with the steepest increases in death, YLL, and DALY rates
are in the lower or uppermiddle-income group.
Atrial fibrillation burden is multifactorial, and, there-
fore, it is not possible to identify one single reason to ex-
plain these trends. It is related to epidemiological
transition, a phenomenon partly driven by income level.
Analyzing the current trends, we can see three stages of AF
burden evolution worldwide. First, a stage of low preva-
lence and consequent low mortality, influenced by the ex-
istence of competing premature death. Low-income
countries may still be facing this scenario, mostly due to
the premature mortality caused by infection, injury, and
ischaemic heart disease.39–42 Additionally, limited health
care access and consequent underdiagnosing in economi-
cally deprived areas should be considered in the interpre-
tation of this low burden.43 In the second stage, as the
causes of premature mortality are progressively avoided,
there is a rise in AF prevalence and mortality. Finally, a
third stage is a decline in AF burden, mainly due to improv-
ing treatment and control of risk factors. Bearing in mind
this evolution, it is reasonable to consider that (i) the rise
in AF mortality-related and total burden currently found
for middle-income countries will be seen in low-income
countries in the future and (ii) the fall in AF morbidity-
related burden currently seen in high-income countries is
yet to be seen in middle- and low- income countries. Taken
together, these trends suggest that, in the next decades,
LMICs will be responsible for an escalating proportion of
global AF burden. Reducing AF burden in the coming deca-
des will probably bemore challenging, and it will be crucial
to consider the specifics of healthcare systems in LMICs to
achieve this goal.
Anticoagulants for stroke prevention
An overview of the available literature on the use of antico-
agulants for stroke prevention in LMICs needs to be contex-
tualized. Most studies presenting data about the use of
anticoagulants as a seminal pathway to the treatment of
AF are from the USA and Europe.44,45 Even when other
countries from Asia, Latin America, or Africa are
included,46 they are not usually LMICs as there are few
studies describing the treatment of AF in LMICs compared
with the number of studies focusing high-income countries.
In large and multicenter studies, individuals from LMICs are
part of the sample, but frequently the results are not pre-
sented by continent or region, which impairs access to spe-
cific information from these countries.47
Some initiatives in LMICs to conduct registries of AF have
appeared in recent years, such as The Mexican Registry of
Atrial Fibrillation (Registro Mexicano de Fibrilación
Auricular—ReMeFa),48 the Atrial Fibrillation and Embolic
Risk Registry (CARMEN-AF),49 both in Mexico, and the
Brazilian Cardiovascular Registry of Atrial Fibrillation (the
RECALL Study) in Brazil.50 However, some of them have not
published data until now.48,50
Another challenge in LMICs data interpretation is the
heterogeneity in the presentation of results, including in-
complete reporting. Only recent studies present results
according to CHADS2 or CHA2DS2-VASc scores.
51–56
Moreover, an expressive number of recent studies do not
present results according to these scores yet.57–60
Additionally studies in LMICs rarely involve population- or
community-based samples.12,13,61 One study used data
from National Health Care Systems,62 which may be resem-
ble more the general population, although the proximity
depends on how national systems of care are organized.
Most samples are from hospitals,55,57,59,63–65 outpatient
departments,66,67 or anticoagulation clinics,68,69 which of-
ten reflect more selective samples. Designs also vary
widely, including cross-sectional or registry studies,52,54,57
cohort studies,58,70 and systematic reviews,71 limiting
comparability.
Figure 3 and Supplementary material online, Table S2
describe LMIC studies about oral anticoagulant (OAC) use
for stroke prevention in patients with AF.12,31,51–59,61–
67,70,72–77 We excluded multicentric studies including both
LMICs and high-income countries, from which it was not
possible to retrieve the LMIC results separately. Of the
studies in Supplementary material online, Table S2, 20
have information about a single country; 2 have informa-
tion describing several LMIC countries but presenting
Figure 1 Atrial fibrillation prevalence rates in low- and middle-income countries, according to sex.
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Figure 2 Epidemiological trends for atrial fibrillation, from 1990 to 2017, according to the World Bank income groups.
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consolidated results54,70 and 2 have information about
more than one country, with results stratified by loca-
tion.62,72 The Realize AF Survey51 presented two arms, one
with African countries and Lebanon and the other with
Latin American countries. In that study, results are pre-
sented for each of these groups. The RE-LY International
Registry57 results were divided into South American and
African countries, India, and China. Due to its intrinsic na-
ture, in studies based in anticoagulation clinics all patients
receive OAC therapy.68,69,78–80 Therefore, we opted to re-
move these articles from our review.
The new ESC 2020 AF guidelines for OAC therapy high-
light the importance of considering stroke prevention in
higher risk men with CHA2DS2-VASc scores 1 or women
with CHA2DS2-VASc scores 2. For men with CHA2DS2-VASc
score ¼ 1 and women with CHA2DS2-VASc scores ¼ 2, OAC
therapy should be considered, while for those with higher
scores, OAC therapy is recommended. NOACs are generally
recommended as the first line therapy, but vitamin K
antagonists (VKAs) can be used as an alternative, ensuring
a high time within the therapeutic range (TTR) is achieved
(at least two-thirds). It is important to address modifiable
bleeding risk factors in all patients with AF. However, high
bleeding risk scores should be used to identify patients who
need strict follow-up and frequent re-evaluations rather
than as a reason to withhold OAC therapy.81
Only 13 studies present data describing anticoagulation
according to participants’ CHADS2 or CHA2DS2-VASc
scores.51–54,57–59,63,66,72,78–80 In these studies, underuse of
OAC is relatively common, with a high proportion of
patients with CHA2DS2 or CHA2DS2-VASc scores 2 using
only antiplatelets (APT) or nothing. The non-prescription
of OAC in these studies cannot be explained by a high risk
of bleeding, since HAS-BLED was calculated in only four of
these studies.52,58,59,80
Gamra et al.51 compared OAC therapy prescription by
geographic region. They assessed compliance with the
2006 American College of Cardiology (ACC)/American
Heart Association (AHA)/European Society of Cardiology
(ESC) guidelines (which were relevant to patients enrolled
between 2009 and 2010). They concluded that appropriate
antithrombotic treatment was prescribed in 66.7% of the
patients with CHADS2 score2 in Middle East/Africa, 55.3%
in Europe, 43.9% in Latin America, and 31.7% in Asia.
In a study by Oldgren et al.,57 the prescription of OAC
therapy in India, China, South American (Argentina, Brazil,
Chile, Colombia, Ecuador, and Venezuela), and African
countries (Cameroon, Kenya, Mozambique, Nigeria,
Senegal, South Africa, Sudan, Tanzania, Uganda, and
Zambia) was compared with the global rates. This propor-
tionwas 45% of individuals with CHA2DS2-VASc scores2 re-
ceiving OAC therapy in South American countries, 40% in
India, 39% in African countries, and 11% in China compared
with the global proportion of 44%. High-income regions,
such as North America and Western Europe, presented pro-
portions at 66% and 63%, respectively. Eastern Europe pre-
sented 39%, closer to the global findings.
The Prospective Urban Rural Epidemiology (PURE) study,
a prospective population-based cohort in 27 geographical
regions of the world, presented information about anti-
thrombotic therapy use in their sample. Overall, 70% of
participants with AF had a CHADS2 score 1, with a similar
Figure 3 Oral anticoagulant therapy for high stroke risk patients with atrial fibrillation in low- and middle-income countries.
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distribution in high-income countries (74%) and LMICs
(70%). Overall, use of stroke prevention medication was
low. There were also differences between these country
groups, with warfarin more commonly used in high-income
countries and antiplatelet usemore common in LMICs.82
A recent systematic review of African AF studies states
that AF is frequently under-reported in the published liter-
ature. Prevalence studies in Africa are scarce, and data
about AF management is even scarcer. As most studies are
performed in different populations, using different designs
and different strategies to collect data, the results are
very heterogeneous.71
It is important to highlight that use of OAC is the first
step to preventing ischaemic stroke in patients with AF.
However, in patients using VKAs, another important step is
to maintain patients at a high time within TTR for effective
stroke prevention. Most studies describing OAC do not in-
clude information about time in TTR. Another important
point is that the new ESC guidelines refine the use of OAC
according to sex, with different cut-off points in treatment
recommendations betweenmen and women.81 No study in-
cluded in this review presented results according to sex.
This is another consideration in the care of LMIC patients
with AF. Due to the challenges associated with maintaining
a high TTR, the non-vitamin K antagonist oral anticoagu-
lants (NOACs) would bemore effective than VKAs in clinical
practice. However, the main barrier to the use of NOACs is
the price of the drugs, which is too high, especially for
widespread use in LMICs. The price of NOACs may be an
even greater barrier in LMICs compared with high-income
countries, deepening the social inequalities in treatment
of AF. Although there is a decrease in laboratory costs, as
prothrombin time determination is not necessary, public
health policies in several LMICs must be implemented to
make the change from VKAs to NOACs. Patents expiration
and the consequent drop in prices may help adopting these
policies in the future.
Although we focused on OAC undertreatment in LMICs, it
is important to acknowledge this problem is not limited to
this setting. A recent systematic review,83 with data from
several studies, including some high-income countries,
showed that treatment of AF with OAC does not follow pub-
lished treatment guidelines and a significant proportion of
patients are exposed to high risk of ischaemic stroke with
high costs to health systems.
Health outcomes
In Table 1, we summarize the main findings from published
studies set in LMICs in the last decade that evaluated fatal
(all-cause, cardiovascular, non-cardiovascular causes of
death) and non-fatal outcomes (stroke, major bleeding and
dementia) related to AF in clinical and non-clinical set-
tings.15,54,84–88 Systemic embolism is an additional AF-
related outcome. However, it is relatively rare, and usually
described with stroke as a combined endpoint. Among the
outcomes most frequently evaluated in these studies, mor-
tality rate has high impact in LMICs, particularly when data
are compared with rates reported in high-income
countries.85,86
Fatal outcomes
Recently, two major AF registries involving LMICs have
clearly documented the difference in the case-fatality
rates, which are highest in low-income areas.85,86 In the
RE-LY Atrial Fibrillation Registry and Cohort Study
Investigators, 1-year mortality was evaluated in 47 coun-
tries. This registry, comprising more than 15000 partici-
pants, compared data from low-middle income regions
(South America, Eastern Europe, Middle East, Africa, India,
China, and Southeast Asia) with high-income regions (North
America, western Europe, and Australia), which were con-
sidered the reference.85 The main findings revealed that
the proportion of adults over 60years who died 1 year post-
emergency department (ED) attendance due to AF/flutter
as primary or secondary diagnosis, was approximately dou-
ble in South America (192/1132; 17%) and Africa (225/
1137; 20%) compared with the reference countries (366/
3800; 10%). Although these rates are unadjusted for poten-
tial confounders, such as age, the African population was
approximately a decade younger than that from the high-
income, while and poor outcomes were more frequently
observed in Africa.85 These findings can be partly explained
by low investment in the public healthcare system and by
the lack of primary prevention action within the young-
middle age population in LMICs.2,85
Similarly, the Global Anticoagulant Registry in the FIELD-
Atrial Fibrillation (GARFIELD-AF) study, which had more
than 52000 participants, observed markedly higher all-
cause mortality rates 1 year after newly diagnosed non-
valvular AF in India [7.68/100 person-years; 95% confi-
dence interval (CI): 6.32–9.35] compared with 35 other
countries worldwide from America, Europe, Africa, and
Asia involved in this registry (4.34/100 person-years; 95%
CI: 4.16–4.53; P< 0.0001). Cardiovascular mortality was
also higher in Indian patients.86
In Latin America, the GARFIELD-AF reported 1-year mor-
tality data focusing on four countries: Argentina, Brazil,
Chile, and Mexico.54 In this registry, all-cause mortality in
Latin America (5.77/100 person-years, 95% CI: 5.06–6.56)
was higher than the global rates, but lower than in
India.86,90 Considering the four Latin America countries,
the highest unadjusted all-cause mortality rate was
reported in Argentina (6.95/100 person-years, 95% CI:
5.43–8.90) followed by Brazil (6.19/100 person-years, 95%
CI: 4.83–7.94).54
Also, in Latin America, a primary care-based study using
an ECG database from the Telehealth Network of Minas
Gerais, Brazil, reported mortality rates according to the
presence of AF/flutter.89 In that study, the highest all-
cause [multivariable hazard ratio (HR): 2.59, 95% CI: 2.47–
2.73] and cardiovascular disease (CVD) (adjusted HR: 2.62;
95% CI: 2.24–3.06) mortality risks associated with AF were
verified in women.
Unlike most previous AF registries, two Chinese multi-
centre prospective cohorts reported mortality rates based
on information about OAC therapy and the presence of
modifiable risk factors.84,87 In the Yang et al.84 study, 1-
year case-fatality (15.4% vs. 11.1%) and major adverse car-
diovascular events (MACE) (22.8% vs. 17.9%) rates were
higher in participants not receiving OACs. In the Jiang
et al. study, the prognostic value of modifiable risk factors
O66 I.S. Santos et al.
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[smoking, high body mass index (BMI), alcohol use, high to-
tal cholesterol, blood pressure, and fasting plasma glucose]
was evaluated in almost 18000 AF participants, with a
mean follow-up of 2.5 years. It was demonstrated that the
presence of2 risk factors was associated with the highest
risk of CVD mortality (adjusted HR: 2.92, 95% CI: 1.16–
7.36), after multivariate adjustment.87
Non-fatal outcomes
In the RE-LY study, although the lowest stroke rate was ver-
ified in India [20 (<1%) of 2536], the highest number of
strokes occurred in patients from Africa [89 (8%) of 1137],
China [143 (7%) of 2023], and southeast Asia [88 (7%) out of
1331]. Meanwhile, the rate in North America, western
Europe, and Australia was 2% (94/3800). Heart failure was
the main cause of hospital admission 1 year after attending
the ED with the highest proportion of cases in Africa com-
pared with other geographical regions.85 In the GARFIELD-
AF study, major bleeding rates were lower in India (0.31/
100 person-years; 95% CI: 0.12–0.82) compared with the
global average from the same registry (0.84/100 person-
years; 95% CI: 0.76–0.92), but no significant differences
were observed for stroke/systemic embolism or ACS
rates.86 In Latin America,54 reported stroke/systemic em-
bolism and major bleeding rates were 1.58/100 person-
years (95% CI: 1.23–2.02), and 0.99/100 person-years (95%
CI 0.72–1.36), respectively. A Chinese study by Yang et
al.,84 found a significantly lower incidence of MACE events
(17.9% vs. 22.8%), although accompanied by a higher inci-
dence of major bleeding among patients with AF receiving
OAC therapy (3.8% vs. 0.7%). Finally, the relationship be-
tween AF and dementia was investigated in a Brazilian
population-based study,15 performed among the elderly liv-
ing in a deprived neighbourhood in the city of S~ao Paulo.
However, after age-adjustment, the association was not
confirmed in this cross-sectional analysis.
Economic burden
Another way of looking at AF burden is to consider the con-
cept of ‘societal burden’ or ‘economic burden’. This bur-
den includes total costs (both direct and indirect)
associated with AF symptoms, its consequences, treat-
ment, and/or treatment-induced complications. Direct
costs include hospitalization (primarily for stroke, heart
failure, arrhythmia recurrence, or decompensation and
bleeding events), outpatient and home visits, prescrip-
tions, laboratory testing, and long-term care. Economic
burden also includes indirect costs related to loss of pro-
ductivity frommissing work during complications/hospital-
izations or due to permanent disability from ischaemic
stroke and support provided by caregivers. Given that AF-
related strokes are predominantly more severe, cause
more disability and tend to occur in people with more
comorbidities, they result in higher direct costs annually
comparedwith non-AF–related stroke. Furthermore, the fi-
nancial burden is higher for patients and their families in
LMIC countries where there is a greater level of out-of-
pocket expenditure on healthcare. Across all countries
where these issues have been studied, most of the costs
are related to hospitalization.91
The treatment of patients with AF includes prevention of
thromboembolic complications (particularly ischaemic
stroke) and control of symptoms.81 Thus, it includes anti-
thrombotic therapy, management of concomitant condi-
tions, and various strategies for symptom relief including
antiarrhythmic drugs for rate or rhythm control, electrical
cardioversion, and left atrial ablation. Access to all these
possible treatment strategies varies greatly across LMICs.
There is limited information on the true burden of disease,
current management strategies, and cost-effectiveness for
managing patients with AF in LMICs.92
Table 2 summarizes studies that evaluated the economic
burden of AF in LMICs.60,93–97 There are very few studies in
this area. As the incidence of AF in LMICs is on the rise,
more studies are needed to further elucidate the ongoing
and future clinical and economic burdens of AF.
An analysis by Stevens et al.93 estimated the prevalence,
incidence, loss of wellbeing, health system cost, and pro-
ductivity losses for four heart conditions (hypertension,
heart failure, myocardial infarction, and AF) in Brazil. The
authors estimated the annual economic costs of AF in
Brazil to be 1.2 billion USD (2018), 94% of which was attrib-
uted to healthcare costs. In contrast, only 14% of the eco-
nomic cost of hypertension was attributed to healthcare
costs. They also estimated an annual attributable cost of
1003 USD for each patient with AF. The impact of AF on
wellbeing showed that of the 3.2 million DALYs for the four
heart conditions, 9% was due to AF (298000 DALYs). Of the
1.9 million healthy years lost due to disability (YLD), 2%
was due to AF and of the 1.3 million years of life lost due to
premature mortality (YLL), 14% was due to AF. In compari-
son, the total cost of AF care in the USA is 6.65 billion USD
(2005), 75% of which was costs associated with hospitaliza-
tion, and the reported annual healthcare costs of AF range
from 660 to 3286 million euros across Europe,91 which rep-
resents2.5% of total healthcare spending.
In Algeria, Bouame et al.94 estimated the annual cost of
drugs and examinations to be 4.1 million euros and 62 mil-
lion euros for hospitalizations related to AF. Hu et al.,95 in a
hospital-based cohort of patients with AF with embolic
stroke in sixmajor Chinese cities, estimated themean total
direct cost for AF-related stroke to be 5000 USD per
person-year, the major cost driver (61.5%) being hospitali-
zation. Total indirect cost was estimated at 2800 USD,
most of which (63%) was a result of early retirement. Wen
et al.,96 in a retrospective analysis of economic data from
the Beijing urban health insurance database compared the
economic burden of treatment-related costs of stroke
patients with AF vs. those without AF. Overall inpatient
costs and total healthcare costs per patient were nearly
three times as high in patients with AF compared to those
without, partly due to higher frequency of comorbidities in
the former group. Total healthcare cost covered by health
insurance and annualized total healthcare cost per patient
were also higher in the patient group with AF. As a high-
income country comparison, Kim et al.98 evaluated 931 138
patients with AF from the National Health Insurance
Service (NHIS) database in South Korea and found a 420% in-
crease in hospitalizations for AF from 2006 to 2015 (from
AF in low- and middle-income countries O71
767 to 3986 per million Korean population). There are very
few studies about the economic impact of AF in LMICs, and
as the incidence of AF in LMICs is expected to increase,
more studies are needed to further elucidate the ongoing
and future clinical and economic burdens of AF.
A hospital-based study from India97 found that AF-
related stroke had a total mean direct healthcare cost per
patient of 8020 USD during the first year after the stroke,
and 47% of this amount was for the index hospitalization.
Other healthcare costs were related to outpatient care
(40% of total), nursing care, homemodifications, and infor-
mal care (13%).
Another study from Brazil60 evaluated anticoagulation
therapy in 1220 individuals with AF in a private setting.
They found an annual cost of 10679 USD per patient across
the entire cohort (mean follow-up of 1.5 years).
Hospitalizations represented 64% of all costs (6851 USD)
and outpatient costs amounted to 3828 USD (36% of total).
Discussion
To date, AF prevalence is still higher in high-income coun-
tries than in LMICs. This acknowledgment, however, should
not overshadow the impact of AF on the health of LMIC pop-
ulations, where 61% of global DALYs due to AF occur.
Analyzing the data from the previous three decades, we
may predict a progressive concentration of AF burden (in-
cluding AF-related stroke) in LMICs in the coming years.
Oral anticoagulant therapy for AF-related stroke preven-
tion is underused even in high-income countries. It is rea-
sonable to consider this problem has a higher magnitude
compared with high-income countries. Although
Table 2 Economic burden of atrial fibrillation in low- and middle-income countries
Author Year Location Sample and design N Age (years) Results
Stevens et al.93 2018 Brazil Community-based cohort
study with cost of illness
framework based on esti-
mated prevalence
1 202 151
patients with
AF in Brazil
Range: 20þ Annual economic costs: 1.2
billion USD (2018); 94%
attributed to healthcare
costs.
1003 USD per patient-year
Bouame et al.94 2018 Algeria Literature review and cost
estimation based on AF
prevalence
Estimated
Algerian popu-
lation with AF:
187 686
66.7% aged 65þ
(estimative)
Drug cost: 1.5 million euros
Examination cost: 2.6 mil-
lion euros
Hospitalization cost: 62 mil-
lion euros
Economic burden of non-
valvular AF > 65 million
euros
Hu et al.95 2013 China Economic analysis in hospi-
tal-based cohort study of
patients with AF and
ischaemic stroke
300 Mean: 70.2 Mean total direct cost for
AF-related stroke: ap-
proximately 5000 USD per
person-year
Wen et al.96 2017 China Cost study using an urban
health insurance data-
base of individuals with
ischaemic stroke
4061 (992 with
AF)
Mean: 68.5 Individuals with AF-related
stroke had more comor-
bidities and hospitaliza-
tions. They also had
higher cost per hospitali-
zation and total health-
care cost compared to
individuals with stroke
without AF
Silva et al.60 2020 Brazil Retrospective cohort cost
study (private health in-
surance database) using
outpatient anticoagula-
tion clinic data
1220 Mean: 63.9 Annual cost per patient
across the entire cohort
was (10679 USD);
Inpatient costs represented
64% of all costs (6851
USD);
Outpatient costs repre-
sented 36% (3828 USD).
Marfatia et al.97 2014 India Multicentric cost of illness
study using hospital data
of patients with incident
AF-related stroke
400 Mean: 61.4 Total mean direct health-
care costs per patient
amounted to 8020
USD during the first year
(47% due to index
hospitalization)
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conflicting data exist,99 the best system to identify individ-
uals with AF who will benefit from OAC therapy currently is
the CHA2DS2-VASc score.
100–102 The prevalence of risk fac-
tors for AF-related stroke (and, consequently, the distribu-
tion of stroke risk stratification score values) differs among
countries, but a substantial proportion of articles included
in this review does not present information about CHA2DS2-
VASc scores. This is an important current gap in knowledge.
In addition, similar CHA2DS2-VASc scores may be associated
with heterogeneous levels of risk across populations, prob-
ably due to multiple factors, as access to healthcare, ad-
herence to treatment, ethnic characteristics (especially in
highly admixed populations), or genetic predisposition.103
Although previous studies have studied the prediction ac-
curacy of CHA2DS2-VASc scores for AF-related stroke in
some LMIC settings,104–106 information from these countries
are scarcer compared with those from high-income coun-
tries.107 This highlights the importance of future observa-
tional studies to validate and refine stroke risk prediction
in LMICs.
Some LMIC features will make stroke prevention in these
locations an increasingly challenging situation. First, bar-
riers to health care access in LMICs108 are usually greater
than in high-income nations. Second, the advances brought
by NOACs in long-term OAC therapy also come with an ini-
tial rise in treatment costs. The widespread adoption of a
more expensive medication would represent a new cost for
LMICs. Although there is evidence this is counteracted by
other costs in patient care, such as visits needed tomonitor
VKA action and event costs,109 this investment may be cur-
rently unaffordable for LMICs due to other pressing
demands from the healthcare sector. Future patent expira-
tions will probably change this scenario, and most likely
represent an important stimulus to the adoption of NOACs.
Lastly, the structure and expenditures of national health
systems vary widely in LMICs which range from conflict-
affected states to countries withmature health systems.110
Currently most LMICs do not have a healthcare structure
capable of managing OAC, as WHO data about healthcare
coverage shows. The WHO Universal Health Coverage
(UHC) index of service coverage ranges from zero to one
and summarizes indicators about how health service cover-
age is improving across the world.111 In 2017, this index
was 0.82 for high-income countries, while upper-middle,
lower-middle, and low-income countries had indexes of
0.77, 0.55, and 0.43, respectively.112 Moreover, there are
large gaps in the service capacity and access component of
the index among income country groups. For example, al-
though the score for high-income country group is over 90%
for this component, the low-income country group scores
slightly above 20%. An out-of-pocket cost (OPC) is a direct
payment of money that may or may not be later reim-
bursed from a third-party source, such as a health insur-
ance company. It is another healthcare system feature that
may influence the adoption of effective strategies for AF
treatment and stroke prevention. OPC also vary widely
across national health systems. In general, the lower the
per capita income, the higher the OPC proportion among
total health costs. OPC proportions in high-, upper-middle,
lower-middle, and low-income groups are 13.6%, 32.9%,
55.7%, and 51.5%, respectively. Looking at these ratios,
however, masks intense differences among countries in the
same groups. In 2017, OPC proportions varied from 0.9%
(Nauru) to 48.9% (Mauritius) in high-income countries, 0.5%
(Tuvalu) to 84.3% (Armenia) in upper-middle income coun-
tries, 0.1% (Kiribati) to 77.2% (Nigeria) in lower-middle in-
come countries, and 6.2% (Rwanda) to 75.5% (Afghanistan)
in low-income countries.113
Besides a low use of OAC therapy, this review reports a
widespread use of aspirin for stroke prevention in LMICs, a
characteristic present in high-income countries,114 but
with lower magnitude compared with LMICs. This poses an
additional challenge to achieve adequate levels of OAC use
for stroke prevention in LMICs. Aspirin, alone or in combi-
nation with other antiplatelets, is incorrectly perceived as
a ‘soft’ choice for stroke prevention in patients with AF,
with a combination of fair efficacy and low bleeding
risk.115,116 Both perceptions are not true, as recognized by
the recent 2020 ESC guidelines.81 Improving physician and
patients’ perceptions about the balance of benefits and
risks of anticoagulation for patients with AF and high stroke
risk is an important objective to overcome this scenario in
LMICs.117 However, this is probably not only a problem of
incorrect perceptions and, eventually, lack of knowledge.
Especially in LMICs, many physicians may be afraid to initi-
ate warfarin therapy for a patient who would not have ade-
quate follow-up to ensure INR control and a high TTR. This
is potentialized by the possibility of being held accountable
for harmful effects of the drug.118 Some strategies must be
considered to increase adequate OAC use in patients with
AF, including educational interventions, providing ade-
quate support for OAC management with warfarin and
higher availability and access to NOAC. Future studies using
both quantitative and qualitative methodologies are
needed to further specify the reasons for the incorrect use
of antiplatelets for stroke prevention, disclosing opportuni-
ties for effective interventions.
Therefore, local data are needed to guide the allocation
of resources in countries living in similar conditions. In addi-
tion, LMICs encompass remarkably diverse ethnicities, and
this affects stroke prevention strategies for patients with AF
due to multiple reasons.119 First, as discussed earlier, there
is evidence that the prevalences of AF-related stroke risk
factors differ, and even similar stroke risk scoresmay repre-
sent heterogeneous levels of risk among different popula-
tions. Second, racial disparities in health access and quality
of care do exist, also explaining part of the higher stroke risk
in minority groups.120 For example, the REasons for
Geographic and Racial Differences in Stroke (REGARDS)
study showed that Black individuals with AF in the USA had
lower odds to be aware of the diagnosis and to receive war-
farin treatment, compared to White individuals.121
Although this studywas conducted in a high-income country,
it is highly likely that minority or more deprived groups in
LMICs face similar or worse difficulties. Third, warfarin
doses to achieve the therapeutic range are influenced by
some genetic variants, as in CYP2C9 and VKORC1
genes,122,123 reinforcing the need for adequate support for
VKAdose control to ensure safeOAC therapy and a high TTR.
The available data also point to a higher morbimortality
per patient with AF in LMICs compared to their counter-
parts in high-income countries. Although data on the
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consequent economic burden in LMICs are scarce, it is rea-
sonable to consider it will follow the same trend as ob-
served for morbimortality.
In conclusion, AF incurs in significant burden in LMICs,
and this scenario is expected to become even more impor-
tant in the next decades. Adequate visibility of AF as a pub-
lic health problem in LMICs is necessary as a first step to
overcoming the stated difficulties and to provide adequate
care for these patients. Given the high heterogeneity
among LMICs, it is very unlikely that a ‘one size fits all’
strategy would be efficient for stroke prevention in this
scenario. This makes obtaining reliable local data a sensi-
tive point to implement public health policies.
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Kaboré P, Kologo K, Zabsonré P. Non valvular atrial fibrillation re-
lated ischaemic stroke at the teaching hospital of Yalgado
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